Search Technologies

Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of cnidarins.

The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing therapeutic agents that generate Nitroxyl (HNO) in physiological media.

The National Cancer Institute’s Chemical Biology Laboratory seeks partners interested in collaborative research to co-develop nitric oxide (NO) based prodrugs for the treatment of lung cancer.

To improve the transduction efficiency the inventors at the National Eye Institute (NEI) have developed a novel, non-invasive approach of applying electric current in combination with a gene therapy vector. This minimally invasive strategy significantly improves the transduction efficiency of AAV vectors in the mouse retina. This represents an improved method for restoring high levels of RS1 expression in the retina of X-linked retinoschisis (XLRS) patients. The NEI seeks a licensing and/or co-development partner to commercialize its AAV-RS1 Gene Therapy for XLRS.

Researchers at the NCI have developed novel T Cell Receptors that target the melanoma antigen, gp100, expressed by human cancers. These TCRs provide superior biological function making them ideal for adoptive immunotherapy. NCI Seeks parties to license or co-develop these TCRs.

Researchers at the National Cancer Institute (NCI) have developed a new format for expressing Chimeric Antigen Receptors (CARs) that is available for licensing and co-development. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. The novel technology is useful for improving CAR therapies to treat a range of cancers.

The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a treatment for Ewing's Sarcoma, with a goal of preclinical evaluation leading to clinical testing.

The National Cancer Institute (NCI) seeks research a co-development partner and/or licensees for applications utilizing the nanoparticle platform technology for delivery of cancer-specific microRNAs, particularly for therapeutic uses in surface cancers, such as mesothelioma.

The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present technology discloses novel RNA  and RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. The National Cancer Institute sees parties interested licensing this technology  or in collaborative research to co-develop RNAi-based nanoparticle therapeutics for cancer and HIV.